Verrica Pharmaceuticals Inc. (VRCA) Tops Q2 EPS by 4c

Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) reported Q2 EPS of ($0.37), $0.04 better than the analyst estimate of ($0.41). Revenue for the quarter came in at $5.18 million versus the consensus estimate of $4.58 million.

For earnings history and earnings-related data on Verrica Pharmaceuticals Inc. (VRCA) click here.

You May Also Be Interested In

• Meta CEO Mark Zuckerberg Says In Internal Town Hall That Ai Agent Development Over The Last Four Months Hasn't 'accelerated In The Way We Expected' - Reuters
• This stock is best-positioned to benefit from the massive increase in data center capex
• Tesla Caps Employee AI Spend At $200 A Week - Information